DarioHealth announced today that it is expanding its digital chronic-disease-management business beyond diabetes and hypertension with the purchase of Upright Technologies, a musculoskeletal (MSK) health company that specializes in connected posture correction devices and digital coaching.
The deal is expected to close on or around February 7, and will run DarioHealth $31 million to complete the...
Dexcom continuous glucose monitor users and their caregivers found themselves in the dark this weekend when a key monitoring feature ceased to function with little to no warning.
The feature, called Dexcom Follow, transmits an alert when a CGM user’s blood sugar reaches a dangerous level and is often used by parents monitoring their children’s condition. When unexpected issues brought down the...
The FDA has issued a class two device recall for Senseonics’ Eversense continuous glucose monitoring system. This posting follows a September notice from the company that alerted providers and distributors in the US that the sensors of certain devices may stop working prematurely.
Senseonics identified a small number of Eversense Sensors that have prematurely stopped functioning due to inadequate...
A study published in the New England Journal of Medicine found that Type 1 diabetes patients using a closed-loop system spent a higher percentage of time in their target glucose range than their peers using a sensor-augmented pump.
Researchers also found that the glycated hemoglobin level of patients using the closed-loop system improved during the study. Conversely, on average patients in the...
Aggregated real-world outcome data collected from thousands of Medtronic MiniMed 670G users indicate that patients on the system spend an average 71% of their time within an optimal glycemic range.
Collected from nearly 8 million days of recorded system use and announced by Medtronic today in a press release, the new findings also suggest that this rate increased further for those who employed...
On Friday, the FDA issued a warning to patients and providers describing the dangers of diabetes management devices and software that haven’t been assessed by the agency. These include any unapproved or unauthorized continuous glucose monitors, insulin pumps and automated insulin dosing systems, whether used as a standalone device or integrated as part of a glucose management system.
“These...
